PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · IEX Real-Time Price · USD
1.540
-0.050 (-3.14%)
Jul 22, 2024, 9:31 AM EDT - Market open
PMV Pharmaceuticals Employees
PMV Pharmaceuticals had 63 employees as of December 31, 2023. The number of employees increased by 1 or 1.61% compared to the previous year.
Employees
63
Change (1Y)
1
Growth (1Y)
1.61%
Revenue / Employee
n/a
Profits / Employee
-$1,033,365
Market Cap
80.25M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63 | 1 | 1.61% |
Dec 31, 2022 | 62 | 8 | 14.81% |
Dec 31, 2021 | 54 | 10 | 22.73% |
Dec 31, 2020 | 44 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Protalix BioTherapeutics | 208 |
DBV Technologies | 105 |
Chimerix | 72 |
Boundless Bio | 72 |
Leap Therapeutics | 54 |
Ikena Oncology | 43 |
SCYNEXIS | 29 |
Nutriband | 13 |
PMVP News
- 7 weeks ago - Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator - Business Wire
- 2 months ago - PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 4 months ago - PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors - GlobeNewsWire
- 4 months ago - PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer - GlobeNewsWire
- 5 months ago - PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights - GlobeNewsWire
- 6 months ago - PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway - GlobeNewsWire
- 7 months ago - PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development - GlobeNewsWire
- 9 months ago - PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights - GlobeNewsWire